BF Biosciences is a biopharmaceutical company developing and manufacturing life-saving drugs for serious conditions like cancer and hepatitis. As Pakistan's first USFDA-standard biopharmaceutical production facility, they focus on making advanced therapies accessible and affordable for patients with unmet medical needs.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with serious conditions such as cancer, hepatitis, and cardiovascular diseases often face challenges in accessing advanced and affordable therapies. The development and manufacturing of complex biological medicines require specialized facilities and adherence to stringent regulatory standards, which can limit availability and increase costs.
Solution
BF Biosciences Limited is a biotechnology pharmaceutical company that addresses these challenges by developing and manufacturing life-saving drugs. As Pakistan's first biopharmaceutical production facility designed to USFDA standards, BF Biosciences focuses on bringing advanced therapies to market at accessible price points. The company's commitment extends to areas with significant unmet patient needs, including oncology, hepatology, and cardiology. Through strategic partnerships and investment in state-of-the-art manufacturing capabilities, BF Biosciences aims to improve patient outcomes and expand access to critical treatments.
Target Audience
The primary target audience includes healthcare professionals, such as physicians and specialists treating patients with oncology, hepatology, cardiology, and other critical diseases. The company also serves patients seeking access to advanced and affordable pharmaceutical treatments.
Features
- Pakistan's first biopharmaceutical production facility designed to USFDA standards.
- Manufacturing capabilities for biological medicines, including treatments for cancer and hepatitis.
- Focus on producing high-quality branded generics and advanced therapies.
- Facility designed and installed by European pharmaceutical designers "Telstar Projects" to comply with EMEA and USFDA standards.
- Equipment designed for complete segregation between different product formulations, including biologicals, vaccines, and other parenterals.
- Adherence to stringent clean room protocols, including special gowning and ventilated systems for H14 cleanliness.
- Licensed by Gilead Sciences, Inc. for the manufacture and sale of Remdesivir, an anti-viral drug.
- Expansion project ("Line II") to increase production capacity for biologicals, non-biologicals, and select vaccines, featuring high-speed pre-filled syringes, a lyophilizer, and combi filling lines.